UBS Group AG reduced its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) by 14.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,223 shares of the company's stock after selling 24,463 shares during the quarter. UBS Group AG owned 0.84% of Global X Genomics & Biotechnology ETF worth $1,747,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Simplex Trading LLC lifted its position in Global X Genomics & Biotechnology ETF by 198.6% during the 3rd quarter. Simplex Trading LLC now owns 2,311 shares of the company's stock worth $29,000 after buying an additional 1,537 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in Global X Genomics & Biotechnology ETF by 26.2% during the 3rd quarter. Avantax Advisory Services Inc. now owns 26,650 shares of the company's stock worth $334,000 after buying an additional 5,539 shares in the last quarter. Portland Global Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 6.0% during the 3rd quarter. Portland Global Advisors LLC now owns 211,040 shares of the company's stock worth $2,649,000 after buying an additional 11,925 shares in the last quarter. Sightline Wealth Advisors LLC lifted its position in Global X Genomics & Biotechnology ETF by 32.9% during the 3rd quarter. Sightline Wealth Advisors LLC now owns 54,420 shares of the company's stock worth $685,000 after buying an additional 13,458 shares in the last quarter. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter worth about $175,000. 56.95% of the stock is owned by institutional investors.
Get
Global X Genomics & Biotechnology ETF alerts:
Global X Genomics & Biotechnology ETF Price Performance
Shares of NASDAQ:GNOM opened at $12.58 on Thursday. The company's 50-day moving average price is $13.16 and its two-hundred day moving average price is $13.13. Global X Genomics & Biotechnology ETF has a one year low of $10.48 and a one year high of $16.75. The stock has a market capitalization of $211.09 million, a PE ratio of -5.38 and a beta of 1.02.
Global X Genomics & Biotechnology ETF Profile
(Get Rating)
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
See Also
- Get a free copy of the StockNews.com research report on Global X Genomics & Biotechnology ETF (GNOM)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
瑞银集团(UBS Group AG)最近向美国证券交易委员会(Securities And Exchange Commission)提交的13F文件显示,今年第三季度,瑞银集团减持了全球X基因组学生物技术ETF(纳斯达克代码:GNOM-GET Rating)14.9%的股份。该机构投资者在本季度出售了24,463股后,持有该公司139,223股股票。据最近提交给美国证券交易委员会的文件显示,瑞银集团持有Global X基因组生物科技ETF 0.84%的股份,价值1,747,000美元。
其他机构投资者也增持或减持了该公司的股份。Simplex Trading LLC在第三季度将其在全球X基因组和生物技术ETF中的头寸提高了198.6%。Simplex Trading LLC现在拥有2311股该公司股票,价值2.9万美元,上个季度又购买了1537股。AvanTax咨询服务公司在第三季度将其在Global X基因组和生物技术ETF中的头寸提高了26.2%。AvanTax咨询服务公司现在持有26,650股该公司股票,价值334,000美元,该公司在上个季度又购买了5,539股。波特兰全球顾问有限责任公司在第三季度将其在Global X基因组和生物技术ETF中的头寸提高了6.0%。波特兰全球顾问公司现在持有211,040股该公司股票,价值2,649,000美元,上个季度又购买了11,925股。SIGHTLINE Wealth Advisors LLC在第三季度将其在Global X基因组和生物技术ETF中的头寸提高了32.9%。SIGHTLINE Wealth Advisors LLC现在持有54,420股该公司股票,价值685,000美元,上个季度又购买了13,458股。最后,Halbert Hargrove Global Advisors LLC在第三季度购买了Global X基因组和生物技术ETF的新股份,价值约17.5万美元。56.95%的股份由机构投资者持有。
到达
全球X基因组和生物技术ETF警报:
全球X基因组和生物技术ETF价格表现
纳斯达克:GNOM的股价周四开盘报12.58美元。该公司的50日移动均线价格为13.16美元,200日移动均线价格为13.13美元。Global X基因组和生物技术ETF的一年低点为10.48美元,一年高位为16.75美元。该股市值为2.1109亿美元,市盈率为-5.38,贝塔系数为1.02。
全球X基因组和生物技术ETF简介
(获取评级)
完整基因组公司是一家生命科学公司,已经开发了脱氧核糖核酸(DNA)测序平台并将其商业化。其完整的基因组分析平台(CGA)将其人类基因组测序技术与先进的信息学和数据管理软件以及端到端外包服务模式相结合,为其客户提供可用于基于基因组的研究的数据。
另请参阅
- 免费获取StockNews.com关于Global X基因组和生物技术ETF(GNOM)的研究报告
- Meta平台可能迎来迄今最大的开盘创新高
- Penny Stock Vinco Ventures可能成为大赢家
- 芯片设计专家Synopsys是隐藏在众目睽睽之下的宝石吗?
- 你应该在凯西的百货商店里预留一些资本吗?
- CrowdStrike股票:趁热打铁!
获得全球X基因组和生物技术ETF日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收关于Global X基因组学和生物技术ETF及相关公司的最新新闻和分析师评级的每日简明摘要。